Erik T. Engelson

All filings by Erik T. Engelson on record concern Lucira Health, Inc., in the capacity of chief executive. In total, 7 filings cover trades dated from 9 February 2021 to 3 March 2023.

On the open market, the record shows 3 purchases worth €133k and 2 sales worth €620k. On balance, insiders were net sellers of €487k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 option exercise. So far in 2023, the count stands at no purchases and 2 sales.

A typical purchase (the median) is worth €36k. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.

Most recently, on 13 March 2023, the filings show an open-market sale worth €62k in Lucira Health, Inc. The most recent open-market purchase was published on 19 September 2022, 1,496 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.